BET proteins bind chromatin through their two bromodomains (BDs), BD1 and BD2, which specifically recognize histones acetylated on lysines.[10] Numerous small‐molecule BET inhibitors (BETi) have been developed, including several currently in phase II or phase III clinical trials for cancer, diabetes and cardiovascular disease.[8, 11] While many BET inhibitors target both the BD1 and BD2 domains of human BET proteins, efforts are increasingly focused on domain‐selective compounds to avoid the dose‐limiting toxicities observed with pan‐BET inhibitors (reviewed in ref.[12]). This evidence concerns the gene DNER and cardiovascular disorder.